Description

This issue of Vital Signs, released on August 21, 2006, provides a strategic overview of the ways medical device companies can positively impact prostate cancer awareness. Additionally, an emerging company profile is provided for IsoRay Medical, a leader in the development of novel treatment options through the use of radionucleotides. Reimbursement and regulatory news from the FDA and CMS is also provided for the week of August 7 - August 11, 2006.